Mini review

Advances in the development of SUMO specific protease (SENP) inhibitors

Ashutosh Kumar, Kam Y.J. Zhang

Structural Bioinformatics Team, Division of Structural and Synthetic Biology, Center for Life Science Technologies, RIKEN, 1-7-22 Suehiro, Yokohama, Kanagawa 230-0045, Japan

Abstract

Article history:
Received 1 February 2015
Received in revised form 6 March 2015
Accepted 16 March 2015
Available online 24 March 2015

Keywords:
Sumoylation
SUMO
SENP
Prostate cancer
Virtual screening

SUMOylation is a reversible post-translational modification that involves the covalent attachment of small ubiquitin-like modifier (SUMO) proteins to their substrate proteins. Prior to their conjugation, SUMO proteins need to be proteolytically processed from its precursor form to mature or active form. SUMO specific proteases (SEPNPs) are cysteine proteases that cleave the pro or inactive form of SUMO at C-terminus using its hydrolase activity to expose two glycine residues. SENPs also catalyze the de-conjugation of SUMO proteins using their isopeptidase activity, which is crucial for recycling of SUMO from substrate proteins. SENPs are important for maintaining the balance between sumoylated and unsumoylated proteins required for normal cellular physiology. Several studies reported the overexpression of SENPs in disease conditions and highlighted their role in the development of various diseases, especially cancer. In this review, we will address the current biological understanding of various SENP isoforms and their role in the pathogenesis of different cancers and other diseases. We will then discuss the advances in the development of protein-based, peptidyl and small molecule inhibitors of various SENP isoforms. Finally, we will summarize successful examples of computational screening that allowed the identification of SENP inhibitors with therapeutic potential.

© 2015 Kumar and Zhang. Published by Elsevier B.V. on behalf of the Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
AMP intermediate came close as the result of a large conformational change in SUMO E1 [6] which is followed by the transfer of SUMO to the catalytic residue Cys173 on SUMO E1 by the formation of a thioester bond between SUMO C-terminus and Cys173 [6–8]. The next step involves the subsequent transfer of SUMO protein from SUMO E1 to SUMO E2 (also known as Ubc9); again with the formation of a thioester linkage between the C-terminal glycine in SUMO protein and the catalytic Cys93 in SUMO E2. Ubc9 is the only known SUMO E2 enzyme, and its deletion abolishes SUMO conjugation [9–11]. In the last step, Ubc9 catalyzes the covalent attachment of the SUMO protein to the ε-amino group in a specific lysine residue of substrate proteins. SUMO E3 ligase increases the efficiency of this step by associating with both the substrate protein and Ubc9 [12–14].

### 2. SENP and SENP isoforms

Mammalian cells express four SUMO isoforms: SUMO-1, SUMO-2, SUMO-3 and SUMO-4. The mammalian SUMO-2 and SUMO-3 are much more similar to each other than to SUMO-1. SUMO-4 on the other hand is highly homologous with SUMO-2 and SUMO-3, but its expression is limited only to a few tissues and organs, mainly the kidney, lymph and spleen [15,16]. SUMO proteins are expressed as precursors and need to be proteolytically processed from its pro or inactive form to mature form [4,17–21]. Senstrin/SUMO-specific proteases (SENPs) cleave inactive or pro form of SUMO at the C-terminus via its hydrolase activity to expose two glycine residues and thereby generating active or mature SUMO [Fig. 1B] [4,17–21]. In addition to C-terminal proteolytic

---

**Fig. 1.** Sumoylation and desumoylation pathway. (A) In sumoylation, SUMO protein is covalently attached to lysine residues in target proteins via a sequential action of an activating enzyme E1, a conjugating enzyme E2, and a ligase E3. (B) SENPs possess endopeptidase activity to carry out proteolytic processing at the precursor SUMO C-terminus (SUMO-2 C-terminus is shown here) to expose two glycine residues. SENPs also possess isopeptidase activity to release conjugated SUMO from substrate proteins.
processing, SENPs also possess isopeptidase activity that is essential for the recycling of SUMO proteins [4,17–21]. These enzymes specifically cleave the isopeptide bond between the C-terminal glycine of SUMO and the substrate protein lysine thereby releasing the SUMO protein from its substrate (Fig. 1B).

Six SENP isoforms (SENP1, SENP2, SENP3, SENP5, SENP6 and SENP7) have been identified in mammals. These six SENPs can be divided into three sub-families based on their sequence homology, substrate specificity and subcellular localization as shown in Table 1 [4,17–21]. SENP1 and SENP2 constitute the first family and have broad specificity for SUMO-1/2/3. SENP3 and SENP5 form the second family, while the third family has SENP6 and SENP7 as its members. Apart from SENP1 and SENP2, all other SENP isoforms prefer SUMO-2/3 over SUMO-1 for deconjugation. The posttranslational modification of substrate proteins by SUMO-4 has not been observed due to SENP’s inability to proteolytically process SUMO-4 precursor in vivo [16,22]. The maturation of precursor SUMO-4 seems to be inhibited by the presence of Pro90 residue in place of Gln in SUMO-1 [16,22]. Pro90 causes conformational constraint and makes the peptide bond to be cleaved inaccessible to the narrow active site of SENP [22,23]. A P50Q single amino acid mutation made in place of Gln in SUMO-1 cursor SUMO-4 seems to be inhibited by the presence of Pro90 residue [22,23]. The maturation of precursor SUMO-4 precursor in vivo [16,22]. The maturation of precursor SUMO-4 precursor in vivo [16,22]. The maturation of precursor SUMO-4 precursor in vivo [16,22]. The maturation of precursor SUMO-4 precursor in vivo [16,22]. The maturation of precursor SUMO-4 precursor in vivo [16,22].

3. Role of SENPs in the development of various diseases

SENP enzymes play a critical role in maintaining normal cellular physiology by preserving the balance between sumoylated and unsumoylated proteins. Knockout studies in mice have shown that the absence of SENP1 or SENP2 is embryonically lethal [31,32]. However in diseased states, this balance between SUMO modified and non-modified proteins is disrupted due to the altered expression of SENPs. Several studies implicated the role of various SENP isoforms in the development of various diseases, including prostate cancer [31,33–35], thyroid cancer [36], colon cancer [37], pancreatic cancer [38], atherosclerosis [39] and heart diseases [40]. Especially, numerous studies indicated the role of SENPs in prostate cancer development. Androgen receptor (AR) is the most important protein in the development and progression of prostate cancer. SENP1 and SENP2 are involved in the desumoylation of AR and studies have shown that the overexpression of SENP1 increases AR transcriptional activity [41,42]. In prostate cancer, hypoxia-inducible factor 1α (HIF-1α) plays a critical role in regulating the expression of various genes required for enhanced oxygen availability in hypoxic tissue environments [43,44]. The sumoylation of HIF-1α has been reported to have varied outcomes by several groups [31,45–47]. Polycomb chromobox 4 (CBX4) and RWD-containing sumoylation enhancer (RSUME) increased the HIF-1α sumoylation by promoting the transcriptional activity of HIF-1α during hypoxia [47,48]. Moreover, it is proposed that the stability and/or transcriptional activity of HIF-1α have been modulated via different sumoylation patterns by CBX4 and the protein inhibitor of activated STAT protein gamma (PIASγ) [48]. Further, it has been shown that SENP1 is essential for HIF-1α stability and consequently the regulation of hypoxic response [31]. Moreover, the absence of SENP1 resulted in active sumoylation of HIF-1α and ubiquitin dependent degradation [31]. In another study, Bawa-Khalfe et al. [33] demonstrated the high correlation between HIF-1α and SENP1 expression, indicating SENP1’s role in prostate carcinogenesis. Furthermore, the overexpression of SENP1 has been observed in more than half of the studied samples of prostate cancer and prostatic intraepithelial neoplasia lesions [33,35]. Analyzing more than 150 specimens of prostate cancer, Wang et al. also demonstrated the correlation between SENP1 expression and prostate cancer.

### 3.1. Role of SENPs in prostate cancer

Table 1

| SENP isoform | Specificity | Subcellular localization | Enzymatic activity | Amino acid residues | Structural information |
|-------------|-------------|--------------------------|-------------------|--------------------|-----------------------|
| SENP1       | SUMO-1/2/3  | Nucleoplasm              | Precursor processing, isopeptidase | 643                | Apo (1IYC, 2XPH, 2XBE, 2CKG) With SUMO-1 (1IY1, 2G4D) With SUMO-2 (2IYD, 2CKH) With SUMO-1 and substrate RanGAP1 (2IY0) |
| SENP2       | SUMO-1/2/3  | Nuclear pore             | Precursor processing, isopeptidase | 589                | Apo (1THO) With SUMO-1 (1TGZ) With preSUMO-2 (2Z00, 3Z0S) With preSUMO-3 (3I01) With SUMO-1 and substrate RanGAP1 (2I02) With SUMO-2 and substrate RanGAP1 (2I03) |
| SENP3       | SUMO-2/3    | Nucleolus                | Isopeptidase       | 574                | Not available         |
| SENP5       | SUMO-2/3    | Nucleolus                | Precursor processing, isopeptidase | 755                | Not available         |
| SENP6       | SUMO-2/3    | Nucleoplasm              | Isopeptidase       | 1112               | Not available         |
| SENP7       | SUMO-2/3    | Nucleoplasm              | Isopeptidase       | 984                | Apo (3EAY)            |
aggressiveness and recurrence [49]. Other evidences for the role of SENP1 in prostate cancer tumorigenesis include the increase in androgen receptor activity [42] and c-Jun dependent transcription [50]. Xu et al. [37] demonstrated the regulation of in vivo and in vitro growth of colon cancer cells by SENP1. They reported that SENP1 overexpressed in most of the colon cancer tissues and its silencing arrested the cell growth in nude mice and the colony formation in a colon cancer cell line DLD-1. Ma et al. [38] described the overexpression of SENP1 in pancreatic ductal adenocarcinoma in comparison with normal tissue. They further showed that knockdown of SENP1 using siRNA inhibited the growth of pancreatic ductal adenocarcinoma.

Although SENP1 is the most studied isoform, the role of other SENP isoforms in pathogenesis has also been reported. SENP2 associates with MDM2 and regulates its sumoylation levels, which is important for its binding with tumor suppressor p53 [51,52]. On the other hand, SENP2 regulates the stability of β-catenin via a WW domain-containing oxidoreductase (WWOX) and thereby regulates the growth of hepatocellular carcinoma cells [53,54]. SENP2 also contributes to the atherosclerotic plaque formation by regulating the levels of p53 and extracellular signal-regulated kinase-5 (ERK5) under disturbed flow conditions [39]. Furthermore, the overexpression of SENP2 is also associated with congenital heart defects and cardiac dysfunction in murine hearts [40]. Other SENPs, especially SENP3 and SENP5, are also therapeutically relevant, as their elevated expression levels have been observed in prostate, ovarian, lung, colon, oral squamous cell carcinomas and osteosarcoma [55-58]. SENP3 is involved in increasing the transcriptional activity of HIF-1α through the desumoylation of a co-regulator p300 [59]. In another study utilizing gene expression datasets from 1363 patients, Cashman et al. [60] demonstrated the correlation between low expression of SENP5 and breast cancer patient survival.

4. Identification of SENP inhibitors

Since SENPs play a critical role in the development of various diseases including cancer, atherosclerosis and heart diseases, designing and developing novel inhibitors are of paramount importance. Hence, there is a growing interest among researchers to discover selective inhibitors of SENP isoforms. Several groups focused on the development of inhibitors of various SENPs useful as chemical tools for studying biological roles of sumoylation and desumoylation as well as for exploring the therapeutic potential of SENPs.

One of the earliest SENP inhibitor development strategies made use of the full or truncated form of SUMO carrying an electrophilic trap or “warhead” at the C-terminal glycine. In one study, an intein-based method was employed to equip SUMO-1 and other ubiquitin-like proteins with a vinyl sulfone (VS) as an electrophilic trap [61]. These protein-based probes reacted covalently with SENP2 (1 in Fig. 2) and other activating, conjugating and deconjugating enzymes through Michael addition of the catalytic cysteine thiol group with VS moiety. Pre-incubation of SENP2 with n-ethylmaleimide (NEM), an alkylating agent, prevented the formation of SUMO-1–VS-SENP2 conjugate and confirmed that cysteine is required for catalysis [61]. A similar strategy was used by Borodovsky et al. [62] to synthesize several peptides with various portions of the C-terminus of ubiquitin-like modifiers Nedd8, SUMO1, FAT10, Fau, and APG12 equipped with a VS electrophilic trap. A dose-dependent labeling of at least one cell lysate protein by SUMO1-peptide-VS was shown in this study. Dobrota et al. [63] also reported the synthesis of a peptidyl active site probe (2 in Fig. 2) for SENP1 and SENP2 using a similar approach. This compound contains an electrophilic trap glycine fluoromethylketone at the C-terminus of a seven-residue SENP specific peptide (FQQQTGG). In 2011, Ponder et al. [64] reported a small molecule inhibitor (JCP-666, 3 in Fig. 2) of Plasmodium falciparum SENP1 ( PfSENP1 ) by screening a focused library of cysteine protease inhibitors. JCP-666 harbors a reactive aza-epoxide linked to a non-natural peptide backbone and displayed an IC50 of 17.9 μM for PfSENP1. A more stable synthetic analog (VEA-260, 4 in Fig. 2) without the aspartic acid side-chain on the aza-epoxide scaffold showed similar potency against PfSENP1 (16.2 μM). It is interesting to note that both compounds also exhibited excellent potency against human SENP1 and SENP2 [64]. Compound 3 displayed IC50 of 9.0 and 4.7 μM for human SENP1 and SENP2 respectively, while compound 4 showed slightly better activity of 7.1 and 3.7 μM respectively for human SENP1 and SENP2. Using compound 4 as the starting point, Albrow et al. [65] synthesized 16 compounds. The inhibitory potency of these compounds was evaluated against human SENP1, 2, 5, 6 and 7. However, all the synthesized compounds were either less or equipotent as the parent compound. Moreover, these aza-epoxide based active site probes demonstrated high background labeling when...
used in complex proteomes indicating their non-specific nature [65]. In the same report, Albow et al. [65] synthesized another series (11 compounds) of human SENP inhibitors based on the compound 4 scaffold and natural SUMO/ubiquitin amino acid sequence accommodating the acyloxyethyl ketone (AOMK) reactive group. Bioactivity evaluations and subsequent IC_{50} determination of more potent compounds revealed that VEA-499 (5 in Fig. 2) was the most potent inhibitor with IC_{50} values of 3.6 and 0.25 μM for human SENP1 and SENP2 respectively [65]. Furthermore, AOMK based inhibitors were also good active site probes as they exhibited highly specific binding in complex proteomes.

In light of the poor pharmacokinetic properties of peptide inhibitors, Qiao et al. [66] designed and synthesized a series of benzodiazepine based SENP1 inhibitors. SENP1 activity was evaluated using SUMO-CHOP reporter fluorescence assay [67]. Two most potent compounds (compounds 6 and 7 in Fig. 2) displayed IC_{50} of 15.5 and 9.2 μM. Compounds 6 and 7 also inhibited cancer cell growth in vitro with IC_{50} values of 13.0 and 35.7 μM respectively. In another attempt to develop SENP1 inhibitors as potential anti-cancer agents, Uno et al. [68] designed and synthesized 1-[4-((N-benzylamino)phenyl)-3-phenylurea derivatives based on a potent HIF-1α inhibitor. The most potent compound (GN6958, 8 in Fig. 2) displayed selective SENP1 inhibition with an IC_{50} of 29.6 μM. Like the parent compound, compound 8 also suppressed HIF–1α without affecting tubulin expression [68]. Another study reported the down-regulation of SENP1 expression at both mRNA and protein levels by the natural product triptolide and other study reported the down-regulation of SENP1 expression at both mRNA and protein levels by the natural product triptolide [69]. However, the actual mechanism of SENP1 downregulation is not known. Recently utilizing virtual screening approach, several groups reported inhibitors of various SENP isoforms. These include 2-(4-chlorophenyl)-2-oxoethyl 4-benzamidobenzoate analogs. However, no significant improvement in the activity (best IC_{50} of 1.08 μM for compound 10) over the parent compound was observed [70]. Madu et al. [71] virtually screened a 250,000 compound National Cancer Institute library using Glide program to obtain 40 compounds for the evaluation of SENP1 and SENP2 inhibitory activities. A gel-based assay that quantifies the maturation of SUMO-1 and SUMO-2 precursors was used to investigate inhibitory effects. A luciferase based coupled bioluminescent assay was also used to determine the inhibition of SENP7 along with SENP1 and SENP2. Bioassay of initial hits and subsequent analog search revealed compounds with a novel chemotype (compounds 11 and 12 in Table 2) that do not covalently modify the catalytic cysteine. The non-competitive

### Table 2

| SENP target | Structure of representative compounds | Activity of most potent compounds | Virtual screening method used | Reference |
|-------------|--------------------------------------|-----------------------------------|------------------------------|-----------|
| SENP1       | ![SEN1](image1)                      | Compound 9, IC_{50} = 2.38 μM, Compound 10, IC_{50} = 1.08 μM | Molecular docking of 180,000 compound library using Glide program. | Chen et al. [70] |
| SENP1, SENP2, SENP7 | ![SEN1 and SENP2](image2) | Compound 11, SENP1 IC_{50} = 5.9 μM, SENP2 IC_{50} = 2.9 μM, SENP7 IC_{50} = 4.2 μM | Molecular docking of 250,000 compound library using Glide program. | Madu et al. [71] |
| SENP1, SENP2 | ![SEN1 and SENP2](image3) | Compound 13, SENP1 IC_{50} = 9.7 μM, SENP2 IC_{50} = 5.9 μM | Hierarchical virtual screening of ~4 million compound library by shape and electrostatic similarity search using ROCS and EON program. Molecular docking using Glide program prioritized hits for bioassay. | Kumar et al. [72] |
| SENP1       | ![SEN1](image4)                      | Compound 15, IC_{50} = 1.29 μM | Molecular docking of 100,000 compound library using Dock and Autodock program. | Wen et al. [73] |

5. Computational approaches in the identification of SENP inhibitors

In the last two decades, computational approaches have played a noteworthy role in the identification and optimization of small molecule inhibitors of proteins of therapeutic interests [74,75]. Taking advantages of virtual screening over conventional high-throughput screening, several groups employed virtual screening in combination with biological assay to identify small molecule inhibitors of various SENP isoforms [70–73]. Chen et al. [70] reported SENP1 inhibitors which were identified by virtual screening for the first time. They docked SPECS library of about 180,000 compounds to SENP1 from the SENP1–SUMO2–RanGAP1 crystal structure. Thirty-eight compounds were selected and purchased from the top scoring 100 compounds. Assessment of bioactivity utilizing fluorescence based assay resulted in the identification of compound 9 (Table 2) with an IC_{50} of 2.39 μM. Docking predicted binding mode of compound 9 was further used to guide the design and synthesis of 2-(4-chlorophenyl)-2-oxoethyl 4-benzamidobenzoate analogs. However, no significant improvement in the activity (best IC_{50} of 1.08 μM for compound 10) over the parent compound was observed [70]. Madu et al. [71] virtually screened a 250,000 compound National Cancer Institute library using Glide program to obtain 40 compounds for the evaluation of SENP1 and SENP2 inhibitory activities. A gel-based assay that quantifies the maturation of SUMO-1 and SUMO-2 precursors was used to investigate inhibitory effects. A luciferase based coupled bioluminescent assay was also used to determine the inhibition of SENP7 along with SENP1 and SENP2. Bioassay of initial hits and subsequent analog search revealed compounds with a novel chemotype (compounds 11 and 12 in Table 2) that do not covalently modify the catalytic cysteine. The non-competitive
The inhibitory nature of these compounds was confirmed using nuclear magnetic resonance (NMR) and quantitative enzyme kinetic experiments. Employing a combination of hierarchical virtual screening and quantitative FRET based assay, Kumar et al. reported 1,2,5-oxadiazoles as novel inhibitors of SENP1 and SENP2 [72]. An overview of the virtual screening protocol used by Kumar et al. is presented in Fig. 3. In summary, an ~4 M compound library was screened for small molecules that have similar shape and electrostatic properties with the conjugate of SUMO-1 C-terminal residues and substrate lysine. Docking and diversity based selection outlined a set of 49 compounds to be tested for SENP1 and SENP2 inhibitory activities. FRET based assay and subsequent analog search revealed two 1,2,5-oxadiazole core containing scaffolds as a novel class of SENP1 and SENP2 inhibitors. Identified inhibitors were specific to SENP and no detectable inhibition on other proteases, such as papain and trypsin, was observed. Wen et al. [73] also utilized hierarchical virtual screening to identify a novel cell-permeable inhibitor of SENP1. They docked about 100,000 drug-like compounds from SPECS database in a stepwise manner using DOCK and AutoDock program. Cherry picking from the top scoring 500 compounds resulted in the selection of 117 compounds for purchase and evaluation of SENP1 inhibitory activity using a SUMO-CHOP reporter assay [67]. The most potent compound (compound 15 in Table 2) displayed an IC$_{50}$ of 1.29 µM for SENP1. Compound 15 was also re-evaluated using in vitro gel-based SENP activity assay to confirm the inhibitory activity that revealed the inhibition SENP1-mediated cleavage of ΔRanGAP1-SUMO-2. Further biological assay revealed that compound 15 is a relatively specific SENP inhibitor and had little or no effect on the activity of proteasome and other cysteine proteases such as cathepsin B and cathepsin D. Molecular docking was employed to propose a mechanism of inhibition that showed that compound 15 binds in a tunnel preventing the binding of SUMO-1 to SENP1. Computational approaches have been also used indirectly to facilitate SENP inhibitor discovery efforts from various groups. Adopting molecular dynamics simulation and quantum mechanics/molecular mechanics calculations, Shi et al. [76] deciphered the catalytic mechanism of SENP desumoylation. They identified critical residues in SENP1 that might be useful in its inhibitor discovery. In summary, an ~4 M compound library was screened for small molecules that have similar shape and electrostatic properties with the conjugate of SUMO-1 C-terminal residues and substrate lysine.
another study, Kumar et al. demonstrated the inhibition of SENP-SUMO protein–protein interaction as a viable alternative strategy to target the enzymatic site [77].

6. Concluding remarks

As discussed in this review, increasing evidence suggests the role of various SENP isomorphs in the development of a number of diseases, especially prostate cancer. Several studies indicated that inhibition of SENPs might be a good approach to combat various cancers. In recent years, considerable progress has been made towards the identification of small molecule inhibitors of various SENP isomorphs. However, most of the developed inhibitors are only suitable as probe molecules to study the biological mechanism of various SENPs. The therapeutic potential of most of the presently identified inhibitors is limited, as they possess reactive chemical functionalities to facilitate covalent binding with the active site cysteine. Moreover, none of the identified chemical classes is isoform specific. Similar biological mechanisms, structural features and chemistry behind the peptide cleavage make it difficult to identify isoform selective SENP inhibitors. Computational approaches like molecular docking have been successfully employed in recent years to identify chemical scaffolds that are much more amenable for chemical optimization needed for lead development. However, many more drug-like chemical scaffolds need to be identified along with their structural description of binding to exploit the therapeutic potential of SENP inhibitors.

Acknowledgments

We thank Dr. Minoru Yoshida, Dr. Akihiro Ito and the members of our laboratory for the help and discussions. We acknowledge RIKEN, Japan for funding.

References

[1] Zhao J. Sumoylation regulates diverse biological processes. Cell Mol Life Sci 2007;64: 3017–33.
[2] Tang Z, Hecker CM, Scheschnaoka A, Retz H. Protein interactions in the sumoylation cascade: lessons from X-ray structures. FEBS J 2008;275:3033–15.
[3] Sarge KD, Park-Sarge OK. Sumoylation and human disease pathogenesis. Trends Biochem Sci 2009;34:200–5.
[4] Yeh ET. SUMOylation and De-SUMOylation: wrestling with life’s processes. J Biol Chem 2007;8:947–51.
[5] Bernier-Villamor V, Sampson DA, Matunis MJ, Lima CD. Structural basis for SUMO activation and E2 recruitment to E1. EMBO J 2005;24:439–46.
[6] Olsen SK, Capili AD, Lu X, Tan DS, Lima CD. Active site remodelling accompanies the SUMO E1. Nature 2010;463:906–10.
[7] Wilkin KA, Henley JM. Mechanisms, regulation and consequences of protein SUMOylation. Biochem J 2010;428:133–45.
[8] Geiss-Friedlander R, Melchor F. Consequences of SUMOylation: in a decade on. Nat Rev Mol Cell Biol 2007;8:947–56.
[9] Melchior F. SUMO—nonscandalous ubiquitin. Annu Rev Cell Dev Biol 2000;16:591–626.
[10] Bernier-Villamor V, Sampson DA, Matunis MJ, Lima CD. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell 2002;108:345–56.
[11] Bawa-Khalfe T, Cheng J, Lin SH, Ittmann MM, Yeh ET. SENP1 induces prostate intraepithelial neoplasia through multiple mechanisms. J Biol Chem 2010;285:25850–66.
[12] Yamaguchi T, Sharma P, Athanasiou M, Kumar A, Yamada S, et al. Mutation of SENP1/Suft-2 reveals an essential role for desumoylation in mouse development. Mol Cell Biol 2005;25:5171–82.
[13] Bawa-Khalfe T, Cheng J, Bawa T, Lee P, Cong L, Yeh ET. Role of desumoylation in the development of prostate cancer. Neoplasia 2006;8:667–76.
[14] Jacques C, Baris O, Brunier-Mirebeau D, Savageur F, Rodien P, Rohmer V, et al. Two-step differential expression analysis reveals a new set of genes involved in thyroid oncogenic tumors. J Clin Endocrinol Metab 2005;90:2314–20.
[15] Xu Y, Li J, Zuo Y, Deng J, Wang LS, Chen GQ. SUMO-specific protease 1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CKI inhibitors. Cancer Lett 2011;309:78–84.
[16] Ma C, Wu B, Huang X, Yuan Z, Nong K, Dong B, et al. SUMO-specific protease 1 regulates pancreatic cancer cell proliferation and invasion by targeting MPP-9. Tumour Biol 2014;35:1279–329.
[17] Heo KS, Chang E, Le NT, Cushman H, Yeh ET, Fujikawa K, et al. De-SUMOylation enz.
[18] Reverter D, Lima CD. A basis for SUMO protease speci.
[19] Kim EY, Chen L, Ma Y, Yu W, Chang J, Moskowitz IP, et al. Enhanced desumoylation of c-Jun during hypoxia. Cell 2007;131:584–95.
[20] Contin E, Chen L, Kong D, Li J, Xu Y, Long X-D, Wang W, Jiao H-K, Mei Z, et al. Cbx4 governs HIF-1alpha during hypoxia. Cell 2007;131:584–95.
[21] Bawa-Khalfe T, Cheng J, Lin SH, Ittmann MM, Yeh ET. SENP1 induces prostate intraepithelial neoplasia through multiple mechanisms. J Biol Chem 2010;285:25850–66.
[22] Yamaguchi T, Sharma P, Athanasiou M, Kumar A, Yamada S, et al. Mutation of SENP1/Suft-2 reveals an essential role for desumoylation in mouse development. Mol Cell Biol 2005;25:5171–82.
[23] Bawa-Khalfe T, Cheng J, Bawa T, Lee P, Cong L, Yeh ET. Role of desumoylation in the development of prostate cancer. Neoplasia 2006;8:667–76.
[24] Jacques C, Baris O, Brunier-Mirebeau D, Savageur F, Rodien P, Rohmer V, et al. Two-step differential expression analysis reveals a new set of genes involved in thyroid oncogenic tumors. J Clin Endocrinol Metab 2005;90:2314–20.
[25] Xu Y, Li J, Zuo Y, Deng J, Wang LS, Chen GQ. SUMO-specific protease 1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CKI inhibitors. Cancer Lett 2011;309:78–84.
[26] Ma C, Wu B, Huang X, Yuan Z, Nong K, Dong B, et al. SUMO-specific protease 1 regulates pancreatic cancer cell proliferation and invasion by targeting MPP-9. Tumour Biol 2014;35:1279–329.
[27] Heo KS, Chang E, Le NT, Cushman H, Yeh ET, Fujikawa K, et al. De-SUMOylation enz.
[28] Reverter D, Lima CD. A basis for SUMO protease speci.
[29] Kim EY, Chen L, Ma Y, Yu W, Chang J, Moskowitz IP, et al. Enhanced desumoylation of c-Jun during hypoxia. Cell 2007;131:584–95.
[30] Contin E, Chen L, Kong D, Li J, Xu Y, Long X-D, Wang W, Jiao H-K, Mei Z, et al. Cbx4 governs HIF-1alpha during hypoxia. Cell 2007;131:584–95.
[51] Chiu SY, Asai N, Costantini F, Hsu W. SUMO-specific protease 2 is essential for modulating p53-Mdm2 in development of trophoblast stem cell niches and lineages. PLoS Biol 2008;6:e310.

[52] Jiang M, Chiu SY, Hsu W. SUMO-specific protease 2 in Mdm2-mediated regulation of p53. Cell Death Differ 2011;18:1005–15.

[53] Shen HJ, Zhu HY, Yang C, Ji F. SENP2 regulates hepatocellular carcinoma cell growth by modulating the stability of beta-catenin. Asian Pac J Cancer Prev 2012;13:3583–7.

[54] Jiang Q-F, Tian Y-W, Shen Q, Xue H-Z, Li K. SENP2 regulated the stability of β-catenin through WWOX in hepatocellular carcinoma cell. Tumor Biol 2014;35:9677–82.

[55] Han Y, Huang C, Sun X, Xiang B, Wang M, Yeh ETH, et al. SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress. J Biol Chem 2010;285:12906–15.

[56] Sun Z, Hu S, Luo Q, Ye D, Hu D, Chen F. Overexpression of SENP3 in oral squamous cell carcinoma and its association with differentiation. Oncol Rep 2013;29:1701–6.

[57] Wang K, Zhang XC. Inhibition of SENP5 suppresses cell growth and promotes apoptosis in osteosarcoma cells. Exp Ther Med 2014;7:1691–5.

[58] Ding X, Sun J, Wang L, Li G, Shen Y, Zhou X, et al. Overexpression of SENP3 in oral squamous cell carcinoma and its association with differentiation. Oncol Rep 2008;20:1041–5.

[59] Huang C, Han Y, Wang Y, Sun X, Yan S, Yeh ETH, et al. SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 deSUMOylation. EMBO J 2009;28:2748–62.

[60] Cashman R, Cohen H, Ben-Hamo R, Zilberberg A, Efroni S. SENPS mediates breast cancer invasion via a TGFbetaR1 SUMOylation cascade. Oncotarget 2014;5:1071–82.

[61] Hemelaar J, Borodovsky A, Kessler BM, Reverter D, Cook J, Kolli N, et al. Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins. Mol Cell Biol 2004;24:84–95.

[62] Borodovsky A, Ova H, Meester WJ, Venanzi ES, Bogyo MS, Hekking BG, et al. Small-molecule inhibitors and probes for ubiquitin- and ubiquitin-like-proteases. Chembiochem 2005;6:287–91.

[63] Dobrot A, Facsi D, Hláde ND, Roiban G-D, Pop C, Meier VM, et al. Glycine fluoromethylketones as SENP-specific activity based probes. Chembiochem 2012;13:80–4.

[64] Ponder Elizabeth L, Albrow Victoria E, Leader Britanny A, Békés M, Mikolajczyk J, Urla P, et al. Functional characterization of a SUMO deconjugating protease of Plasmodium falciparum using newly identified small molecule inhibitors. Chem Biol 2011;18:711–21.

[65] Albrow Victoria E, Ponder Elizabeth L, Fasci D, Békés M, Deu E, Salvesen GS, et al. Development of small molecule inhibitors and probes of human SUMO deconjugating proteases. Chem Biol 2011;18:722–32.

[66] Qiao Z, Wang W, Wang L, Wen D, Zhao Y, Wang Q, et al. Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors. Bioorg Med Chem Lett 2011;21:6389–92.

[67] Leach C, Tian X, Matterns M, Nicholson B. Detection and characterization of SUMO protease activity using a sensitive enzyme-based reporter assay. In: Uhrich H, editor. SUMO protocols. Humana Press; 2009. p. 269–81.

[68] Uno M, Kona Y, Ban HS, Nakamura H. Discovery of 1-(4-(N-benzylamino)phenyl)-3-phenylurea derivatives as non-peptidic selective SUMO-sentrin specifc protease (SENP1) inhibitors. Bioorg Med Chem Lett 2012;22:5169–73.

[69] Huang W, He T, Chai C, Yang Y, Zheng Y, Zhou P, et al. Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. PLoS One 2012;7:e27693.

[70] Chen Y, Wen D, Huang Z, Huang M, Luo Y, Liu B, et al. 2-(4-Chlorophenyl)-2-oxoethyl 4-benzamidobenzoate derivatives, a novel class of SENP1 inhibitors: virtual screening, synthesis and biological evaluation. Bioorg Med Chem Lett 2012;22:6867–70.

[71] Madu G, Namanja AT, Su Y, Song S, Li Y-J, Chen Y. Identification and characterization of a new chemotype of noncovalent SENP inhibitors. ACS Chem Biol 2013;8:1435–41.

[72] Kumar A, Ito A, Takemoto M, Yoshida M, Zhang KYJ. Identification of 1,2,5-oxadiazoles as a new class of SENP2 inhibitors using structure based virtual screening. J Chem Inf Model 2014;54:870–80.

[73] Wen D, Xu Z, Xia L, Liu X, Tu Y, Lei H, et al. Important role of SUMOylation of spliceosome factors in prostate cancer cells. J Proteome Res 2014;13:3571–82.

[74] Kumar A, Zhang KYJ. Hierarchical virtual screening approaches in small molecule drug discovery. Methods 2015;71:26–37.

[75] Tanrikulu Y, Krüger B, Proschak E. The holistic integration of virtual screening in drug discovery. Drug Discov Today 2013;18:358–64.

[76] Shi T, Han Y, Li W, Zhao Y, Liu Y, Huang Z, et al. Exploring the desumoylation process of SENP1: a study combined MD simulations with QM/MM calculations on SENP1-SUMO1-RanGAP1. J Chem Inf Model 2013;53:2360–8.

[77] Kumar A, Zhang KYJ. Computational investigation of SENP:SUMO protein–protein interaction for structure based drug design. Mol Inform 2013;32:267–80.